Logo
Contact Us
Banner

SIRT6-IN-3

Products

Quote Request

SIRT6-IN-3

SIRT6-IN-3

Catalog No.: PC0025

Size: 50 mg, 100mg, 250mg

Description

SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cell proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) by blocking DNA damage repair pathways. SIRT6-IN-3 for pancreatic cancer research.

Molecular Weight 673.73
Formula C21H30Br3ClN6S
SMILES BrC1=C(Br)NC(C2=NC=CC3=C2N=CN3CCCCCCS/C(N(C)C)=[N+](C)\C)=C1.Cl.[Br-]
Shipping Room temperature in continental US; may vary elsewhere.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro SIRT6-IN-3 (25 μM, 48 h) induces PDAC cell-cycle arrest and apoptosis.
SIRT6-IN-3 (25 μM, 72 h) inhibits the proliferation of pancreatic cancer cells by inhibiting signaling pathways
In Vivo SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) has antitumor effects on tumor mouse model.
SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) enhances the antitumor effects of gemcitabine in vivo when in combination with gemcitabine (ratio 2 : 1)
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Logo

As the scientific machine continues to turn, Alfa Cytology is committed to keeping pace. We continue to expand our services and improve our existing resources to help our customers accelerate their research and support their careers.

Company
Our Services
Our Products

Copyright © Alfa Cytology. All rights reserved.